| "We will look at inorganic growth. We have a strategy to look for an appropriate opportunity. We are looking at how to grow our pharmaceutical business," Biocon Chairperson and Managing Director Kiran Mazumda-Shaw said in an interview. |
| "We will look at an international listing. That's a very important objective for us," Shaw said, and added that "we will do it at a time when we are really in a position to partner one of our programmes at a very, very high valuation." |
| Biocon made a string of announcements in the last couple of months like striking agreements with NASDAQ-listed Abraxis Bioscience and Invitrgogen, setting up a joint venture in Dubai and divesting its enzymes business for $ 115 million. |
| "We focus strongly and have created an infrastructure to address global scale. Now, we are looking at how to access global markets," Majumdar-Shaw said. She said her company planned to take advantage of the large market in West Asia. |
| The Biocon boss said the company would invest more in its discovery programme, which has shown "a lot of promise" and required investment to "unlock huge value". |
| "We divested our enzymes business, so that the realisation can be used to invest in promising research programmes," she said. |
| About the thrust of Biocon, Shaw said efforts were being made to see that the company is able to keep its performance at a certain level, in the face of sharp appreciation of the rupee vis-a-vis the dollar in recent months. |
| "We have already been impacted in the last quarter," she said, and explained that hedging does not completely help companies when the rupee appreciates some 10 per cent in 3-4 months in an "abrupt way". |
| "We are looking at how best to deal with depreciation of the dollar and not let it erode our profits," Majumdar-Shaw said. |
| For the June quarter, Biocon clocked a revenue of Rs 272 crore and a net profit of Rs 53 crore. |
Top Section
Explore Business Standard